Details

Autor(en) / Beteiligte

• Zhu, Xue-Xue
• Meng, Xin-Yu
• Zhang, Ao-yuan
• Zhao, Chen-Yang
• Chang, Chang
• Chen, Tian-Xiao
• Huang, Yan-Bo
• Xu, Jin-Peng
• Fu, Xiao
• Cai, Wei-Wei
• Hou, Bao
• Du, Bin
• Zheng, Guan-Li
• Zhang, Ji-Ru
• Lu, Qing-Bo
• Bai, Ning
• Han, Zhi-Jun
• Bao, Neng
• Qiu, Li-Ying
• Sun, Hai-Jian

Titel

Vaccarin alleviates septic cardiomyopathy by potentiating NLRP3 palmitoylation and inactivation

Ist Teil von

• Phytomedicine (Stuttgart), 2024-08, Vol.131, p.155771, Article 155771

Ort / Verlag

Elsevier GmbH

Erscheinungsjahr

2024

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• Sepsis often leads to significant morbidity and mortality due to severe myocardial injury. As is known, the activation of NOD-like receptor family pyrin domain-containing 3 (NLRP3) inflammasome crucially contributes to septic cardiomyopathy (SCM) by facilitating the secretion of interleukin (IL)-1β and IL-18. The removal of palmitoyl groups from NLRP3 is a crucial step in the activation of the NLRP3 inflammasome. Thus, the potential inhibitors that regulate the palmitoylation and inactivation of NLRP3 may significantly diminish sepsis-induced cardiac dysfunction. The present study sought to explore the effects of the prospective flavonoid compounds targeting NLRP3 on SCM and to elucidate the associated underlying mechanisms. The palmitoylation and activation of NLRP3 were detected in H9c2 cells and C57BL/6 J mice. Echocardiography, histological staining, western blotting, co-immunoprecipitation, qPCR, ELISA and network pharmacology were used to assess the impact of vaccarin (VAC) on SCM in mice subjected to lipopolysaccharide (LPS) injection. From the collection of 74 compounds, we identified that VAC had the strongest capability to suppress NLRP3 luciferase report gene activity in cardiomyocytes, and the anti-inflammatory characteristics of VAC were further ascertained by the network pharmacology. Exposure of LPS triggered apoptosis, inflammation, oxidative stress, mitochondrial disorder in cardiomyocytes. The detrimental alterations were significantly reversed upon VAC treatment in both septic mice and H9c2 cells exposed to LPS. In vivo experiments demonstrated that VAC treatment alleviated septic myocardial injury, indicated by enhanced cardiac function parameters, preserved cardiac structure, and reduced inflammation/oxidative response. Mechanistically, VAC induced NLRP3 palmitoylation to inactivate NLRP3 inflammasome by acting on zDHHC12. In support, the NLRP3 agonist ATP and the acylation inhibitor 2-bromopalmitate (2-BP) prevented the effects of VAC. Our findings suggest that VAC holds promise in protecting against SCM by mitigating cardiac oxidative stress and inflammation via priming NLRP3 palmitoylation and inactivation. These results lay the solid basis for further assessment of the therapeutic potential of VAC against SCM. [Display omitted]